SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that it will host an online virtual R&D day to mainly discuss the Company's pipeline and research. The event will be conducted in two separate sessions, including one Mandarin session (8:00 a.m. to 12:00 p.m. on November 10th, China time) and one English session (9:00 p.m. to 01:00 a.m. (+1 day) November 10th, China time). The agenda and registration information are as follows.
Tuesday, November 10th, 2020
08:00 am - 12:00 pm China/Singapore
Tuesday, November 10th, 2020
09:00 pm - 01:00 am (+1 day) China/Singapore
08:00 am - 12:00 pm U.S. (EST)
01:00 pm - 05:00 pm UK (London Time)
English Session Agenda (China Time)
09:00 pm - 09:30 pm Company Development and Long-term Vision
09:30 pm - 12:00 am Presentation and Discussion on R&D
12:00 am - 01:00 am (+1 day) Panel Discussion
Dr. Michael Yu Founder, Chairman and Chief Executive Officer
Mr. Ronnie Ede Chief Financial Officer and Executive Director
Mr. Min Liu Chief Commercial Officer
Leaders of R&D Team/Clinical Team/Commercial Team/CMC Team/BD Team
Chair: Ms. Anna Zhu, Senior Director of Investor Relation
- Mandarin session registration link: https://b.eqxiu.com/s/vVLSC926
- English session registration link: https://i.eqxiu.com/s/GVhQdkvs
- In order to join the conference call, investors and analysts must pre-register using the link above. Registration is already open. Please pre-register before November 8th（China Time）.
- Once registered and confirmed, an email will be sent with important details for this event such as the link and password. This password is to be kept confidential and not share with other participants.
- Should you have any inquiry, please contact [email protected]
*The event will be conducted in one Mandarin session and one English session that share the same content. Please feel free to sign up your preferred session.
Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with three products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection), on market, one asset under NDA review with priority review status, four assets in Phase 3 or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT® (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.
Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: www.innoventbio.com.
SOURCE Innovent Biologics, Inc.